Evidence map›Paper›PMID 41284725›Full record

ArticlePLoS computational biology2025

TransMarker: Unveiling dynamic network biomarkers in cancer progression through cross-state graph alignment and optimal transport.

Fatemeh Keikha, Chuanyuan Wang, Zhixia Yang, Zhi-Ping Liu

Abstract read
In one paragraph

Article in PLoS computational biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fatemeh KeikhaDepartment of Biomedical Engineering, School of Control Science and Engineering, Shandong University, Jinan, Shandong, China.
Chuanyuan WangDepartment of Biomedical Engineering, School of Control Science and Engineering, Shandong University, Jinan, Shandong, China.
Zhixia YangCollege of Mathematics and Systems Science, Xinjiang University, Urumqi, Xinjiang, China.
Zhi-Ping LiuDepartment of Biomedical Engineering, School of Control Science and Engineering, Shandong University, Jinan, Shandong, China.ORCID 0000-0001-7742-9161

Funding

National Key Research and Development Program of ChinaNational Natural Science Foundation of ChinaShandong Provincial Key Research and Development Program (Major Scientific and Technological Innovation Project)
6 · The paper itself

Abstract

The identification of state specific biomarkers that reflect dynamic changes in gene regulatory networks is critical for understanding cancer progression and enhancing diagnostic precision. While multilayer network models have been proposed for analyzing disease evolution, most existing methods rely solely on topological features, neglecting structural rewiring and expression variability across disease states. In this study, we introduce TransMarker, a framework designed to detect genes with regulatory role transitions, those with meaningful shifts in regulatory roles during disease progression, as dynamic biomarkers via cross-state alignment of multi-state single-cell data. TransMarker encodes each disease state as a distinct layer in a multilayer graph, integrating prior interaction data with state-specific expression to construct attributed gene networks. Contextualized embeddings for each stage are generated for each state using Graph Attention Networks (GATs), and structural shifts are quantified via Gromov-Wasserstein optimal transport. Genes with significant changes are ranked using a Dynamic Network Index (DNI), which captures their regulatory variability. These prioritized biomarkers are then applied in a deep neural network for disease state classification. We validate our approach on synthetic simulated and real world dataset of gastric adenocarcinoma (GAC), to evaluate performance across diverse scenarios and assess generalizability. TransMarker outperforms existing multilayer network ranking techniques in classification accuracy, robustness, and biomarker relevance. Ablation studies confirm the contribution of each step to overall performance. Our findings suggest that combining regulatory rewiring, temporal expression dynamics, and cross-state alignment provides a powerful strategy for identifying biologically meaningful biomarkers and modeling disease progression at single cell resolution.

Indexed as

Biomarkers, TumorGene Regulatory NetworksNeoplasmsAlgorithmsComputational BiologyDisease ProgressionGene Expression Regulation, NeoplasticHumansNeural Networks, ComputerBiomarkers, Tumor

Identifiers

PMID41284725
PMCPMC12668635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.